A5026753967- Digital Innovation in Industries
- Marketing and Advertising Strategies
- Cancer Genomics and Diagnostics
- Management and Marketing Education
- Digital Marketing and Social Media
- International Business and FDI
- Colorectal Cancer Treatments and Studies
- Big Data and Business Intelligence
- Online and Blended Learning
- Advanced Breast Cancer Therapies
- Law, logistics, and international trade
- Urban and Freight Transport Logistics
- Research Data Management Practices
- Strategic Planning and Analysis
- Lung Cancer Treatments and Mutations
- Canadian Policy and Governance
- Genetic factors in colorectal cancer
- Business Strategy and Innovation
- Census and Population Estimation
- Web and Library Services
- Digital Games and Media
- Corporate Governance and Management
- Prostate Cancer Treatment and Research
- Mechatronics Education and Applications
- Pelvic floor disorders treatments
San Jose State University
2021-2025
Guardant (United States)
2021-2025
Silicon Valley University
2022-2024
Hartwick College
2019-2022
University of Warwick
2019-2022
Burlington College
2018
Aptevo Therapeutics (United states)
2017
University of Toronto
2013
Objective: We aimed to estimate the global prevalence of type 2 diabetes over next ten years, taking into account trends in obesity. Our analysis includes estimates for 45 countries representing almost 90% world population. defined a prevalent case as anyone living with diabetes, irrespective whether it has been formally diagnosed or not and excluded 1 cases. Methods: performed systematic search published studies other data sources that reported well any factors may change its risk prognosis...
BackgroundIn estrogen receptor–positive metastatic breast cancer, ESR1 mutations (ESR1m) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh). However, the impact alterations have on CDK4/6 inhibitor (CDK4/6i) sensitivity has not been established. Analyses CDK4/6i trials suggest that endocrine therapy partner and specific allele may affect susceptibility. We analyzed real-world data set investigate efficacy in ESR1m cancer associated clinical factors.MethodsESR1m were...
MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.
The fourth Machine Learning for Health (ML4H) symposium was held in person on December 15th and 16th, 2024, the traditional, ancestral, unceded territories of Musqueam, Squamish, Tsleil-Waututh Nations Vancouver, British Columbia, Canada. included research roundtable sessions to foster discussions between participants senior researchers timely relevant topics ML4H community. organization roundtables at conference involved 13 27 junior chairs across tables. Each session an invited chair (with...
255 Background: Homologous recombination repair (HRR) genes, including DNA are increasingly recognized for impacting treatment resistance and prognosis of metastatic prostate cancer (mPC). Next-generation sequencing circulating tumor (ctDNA) enables non-invasive, longitudinal monitoring molecular alterations in patients (pts) undergoing systemic therapies. This study explores the dynamic changes ctDNA profiles mPC, particularly focusing on HRR alterations. Methods: We utilized...
<sec> <title>BACKGROUND</title> Urinary issues pose a significant burden on healthcare systems, necessitating innovative solutions to enhance patient care and alleviate provider workload. This study investigates providers' perceptions of urinary the acceptability technology in managing these conditions. </sec> <title>OBJECTIVE</title> The objective this was explore professionals' assess their acceptance readiness adopt wearable remote technologies for aimed identify attributes barriers...
Abstract Background Impact of BRAF V600E mutations (BRAFV600E), a poor prognostic factor in metastatic colorectal cancer, is lacking non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumor-agnostic approvals for patients with BRAFV600E, understanding the frequency impact alterations across GI essential clinical decision-making. Methods Patients PDAC, GEA, HCC, or CCA who had...
Abstract Somatic BRAF alterations occur in up to 5% of non-small cell lung cancer (NSCLC) cases and comprise three mechanistically distinct molecular subtypes: Class I (e.g., V600E) function as constitutively active monomers, II that signal RAS-independent mutant homodimers, III activate MAPK signaling via RAS-dependent BRAF/wild-type RAF heterodimers. While V600E (Class I) mutations are effectively targeted by approved therapies against these oncogenic there no established treatments for...
4200 Background: CUP accounts for <5% of cancers and carries a dismal prognosis with median overall survival ~13 months. Studies suggest up to one-third patients (pts) have potentially targetable alteration (PTA) that may be eligible molecularly guided therapy (MGT). Liquid biopsy (LB) is non-invasive method identify PTAs genomic clues regarding primary site via circulating tumor DNA (ctDNA). We characterize the ctDNA landscape in evaluate outcomes pts receiving MGT. Methods: Real-world...
Extracellular matrix changes are often crucial inciting events for fibroproliferative disease. Epigenetic changes, specifically DNA methylation, critical factors underlying differentiated phenotypes. We examined the dependency of matrix-induced fibroproliferation and SMC phenotype on methyltransferases. The cooperativity with growth factors, cell density hypoxia was also examined. Primary rat visceral early passage (0-2) were plated native collagen or damaged/heat-denatured collagen. Hypoxia...
PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) is typically treated with agents directly or indirectly targeting the androgen receptor (AR) pathway. However, such treatment limited by resistance mechanisms, including development of activating mutations in AR ligand-binding domain ( AR-LBD). METHODS This study evaluated a database over 15,000 patients advanced (PC) undergoing comprehensive circulating-tumor DNA analysis (Guardant360, Redwood City, CA) between 2014 and 2021,...
1071 Background: Elacestrant was the first novel endocrine therapy (ET) to receive FDA approval in over two decades. In EMERALD study, pts with ESR1-mutant ( ESR1m) HR+/HER2-negative aBC had a median progression free survival (PFS) of 3.8 months (mos). Here, we use large clinical-genomic database assess RW elacestrant and examine impact line (LOT) number ERS1m on pt outcomes. Methods: Pts HR+/HER2- were identified via GuardantINFORM database; all ESR1m detected circulating tumor DNA (ctDNA)...
Background: To overcome the challenges of delivering patient care in twenty-first century, it is essential to foster professional and personal qualities courage resilience nursing workforce. The logical place do so education training.Objectives/Hypotheses: This paper discusses constructs application education.Design: a discussion article drawing on relevant literature experiences authors develop conceptual model for teaching resilience.Results: promote students' coping strategies their...
56 Background: Identification of MSI-H is clinically meaningful in patients with aGI given the associated approval multiple immune checkpoint inhibitors. has long been assessed via tissue analysis; and insights from plasma-based approaches are limited to small validation studies. We sought assess prevalence initial acquired status across report real-world outcomes colorectal (CRC) who received ICI after identification by a commercially available liquid biopsy (LBx) assay. Methods: Genomic...
9106 Background: The introduction of KRAS G12C inhibitors into clinical trials has demonstrated promise and may provide a new therapeutic option for patients (pts) harboring mutations. Recent data also indicated that immune checkpoint (ICI) have shown benefit in mutant lung adenocarcinoma (LUAD); however, on the impact co-occurring STK11 mutations outcomes are conflicting. We utilized Guardant INFORM real-world clinical-genomic database to assess pts with LUAD treated first-line ICI...
158 Background: Real-world evidence informing on the value of incorporating serial ctDNA into clinical practice is lacking. We aimed to explore utility for identifying mechanisms resistance and new targets patients (pts) receiving anti-EGFR therapy mCRC. Methods: retrospectively reviewed 2801 pts with mCRC who had ≥1 alteration detected a Guardant360 assay (Guardant Health) subsequently assessments known intervening therapies. compared detection MAPK pathway alterations ( RAS/EGFR/BRAFV600...
77 Background: In mCRPC, AR T878 and/or H875 and L702H mutations have been associated with disease progression poor prognosis. This study characterized real-world overall survival (rwOS), testing practices, mutation prevalence, treatment patterns in patients mCRPC without tumors missense the LBD (amino acids 671–920). Methods: this retrospective analysis of Guardant Inform Database (Mar 11, 2014–Jun 30, 2022), men (aged ≥18 y) who were tested Guardant360 (G360) next-generation sequencing...
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are development. However, the heterogeneity levels prior treatment (baseline) across different cancer types stages has not been widely studied. Friends of Cancer Research formed collaboration commercial assay developers assess baseline five early- late-stage disease. This retrospective study included eight providing summary-level de-identified...
Abstract Background: While CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard-of-care first-line (1L) for hormone-positive (HR+), HER2-negative mBC, there ongoing debate regarding optimal use of the three FDA-approved CDK4/6i drugs. All drugs have demonstrated significantly improved progression-free survival (PFS), but only two overall (OS). These trial data prompted selection and sequencing these To further evaluate this, we analyzed a RW clinical-genomic database to explore...
e13627 Background: The analysis of genomic variants is crucial in precision oncology research, offering insights into cancer risks and progression, especially diverse types such as lung adenocarcinoma (LUAD). However, research often grapples with balancing patient privacy the need for comprehensive, high-quality datasets. Our project addresses this by creating synthetic clinical-genomic data, which maintains confidentiality provides a rich resource research. Methods: Leveraging...
We used a real-world database (GuardantINFORMTM) to analyze the treatment choices for patients with mCRC who underwent next-generation sequencing of circulating tumor DNA (ctDNA) using commercially available test (Guardant360®) after first- or second-line therapy. From 18,875 claims CRC, 1064 had confirmed metastatic disease and sufficient histories analysis (median age 59 years, 44.8% female, 44.5% left-sided). ctDNA was detectable 997/1064 (93.7%) patients. Clinically actionable molecular...
Abstract Background: CDK4/6 inhibitors (CDK4/6i) are standard first-line (1L) regimens for HR+/HER2- advanced breast cancer (aBC). Recent data from the randomized phase II MAINTAIN trial reported a PFS benefit patients (pts) who received new endocrine therapy plus ribociclib (ribo) versus alone) following progression on CDK4/6i as compared to pts alone. However, second-line (2L) treatment patterns and patient outcomes 1L relatively undescribed. Here we describe real-world 2L associated...